‘Mistakes’ Can Be Advantageous


A ‘Mistake’ May Have Made a More Efficacious COVID-19 Vaccine

Health Editor’s Note: Surprising information on the COVID-19 vaccine front. AstraZeneca is investigating why one-half dose of the primer vaccine seems to have raised the efficacy of the vaccine. While the half-dose was an error, this dose seems to have been as effective as two full doses and the hypothesis is that the lower dose ‘primed’ the immune system and created a super immune reaction.  Sometimes mistakes happen for a reason as we move toward an effective, safe vaccine against COVID-19…..Carol




We See The World From All Sides and Want YOU To Be Fully Informed
In fact, intentional disinformation is a disgraceful scourge in media today. So to assuage any possible errant incorrect information posted herein, we strongly encourage you to seek corroboration from other non-VT sources before forming an educated opinion.

About VT - Policies & Disclosures - Comment Policy
Due to the nature of uncensored content posted by VT's fully independent international writers, VT cannot guarantee absolute validity. All content is owned by the author exclusively. Expressed opinions are NOT necessarily the views of VT, other authors, affiliates, advertisers, sponsors, partners, or technicians. Some content may be satirical in nature. All images are the full responsibility of the article author and NOT VT.


  1. In the low-dose trial, none of the participants were over 55 years old and the efficacy was 90%. In the full-dose trial the efficacy was 62%. Could this suggest that the vaccine is less effective in the older population that is said to be at an increased risk if they contract Covid-19?
    Since only one of the two doses in the low-dose trial was a half-dose, perhaps it would be informative to test what happens if both doses are half-doses. Also, if the first dose as a half-dose was better than the first dose as a full-dose could a first dose at a quarter-dose produce better results than having the first dose as a half-dose?

Comments are closed.